Annexon Inc (ANNX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $747.79M
Last updated: Nov 17, 2026 at 11:05 AM ET
Annexon Inc (ANNX) Competitors
The companies most similar to Annexon are Alto Neuroscience (ANRO), Syndax Pharmaceuticals (SNDX) and OmniAb (OABI). By market cap, Annexon ranks 6th of the 13 companies on this page; Alto Neuroscience (ANRO) is the largest at $1.18B.
Peer Comparison
ANNX's ROIC of -84.6% is below the peer median of -28.5%, and its revenue growth of 0.0% is in line with the median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Annexon (ANNX) | $747.79M | N/A | N/A | 0.0% | -84.6% | 0.0% | 0.00% |
| Alto Neuroscience, Inc. (ANRO) | $1.18B | N/A | N/A | 0.0% | -23.5% | 0.0% | 0.00% |
| Syndax Pharmaceuticals Inc (SNDX) | $850.77M | N/A | 2.8x | -72.3% | -65.0% | 81.6% | 0.00% |
| OmniAb Inc. (OABI) | $716.17M | N/A | 15.7x | -108.1% | -17.5% | 78.3% | 0.00% |
| Inventiva Sa (IVA) | $879.90M | N/A | 133.4x | 0.0% | -327.7% | -76.7% | 0.00% |
| Climb Bio Inc (CLYM) | $608.53M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Neurogene Inc (NGNE) | $495.37M | N/A | N/A | 0.0% | -28.5% | 0.0% | 0.00% |
| Adlai Nortye Ltd. American Depositary Shares (ANL) | $683.26M | N/A | 8.1x | -124.8% | -7.3% | 178.1% | 0.00% |
| Theravance Biopharma Inc (TBPH) | $884.18M | 95.1x | 8.4x | 51.6% | N/A | -20.9% | 0.00% |
| Janux Therapeutics Inc (JANX) | $695.65M | N/A | 29.6x | 0.0% | N/A | -7.1% | 0.00% |
| Regenxbio Inc (RGNX) | $505.18M | N/A | 3.1x | -113.9% | N/A | -69.2% | 0.00% |
| DBV Technologies (DBVT) | $692.19M | N/A | N/A | 0.0% | -130.3% | -42.9% | 0.00% |
| Jade Biosciences, Inc. (JBIO) | $1.03B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $705.91M | 95.1x | 8.4x | 0.0% | -28.5% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Annexon, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. | ANRO competitors |
| Syndax Pharmaceuticals Inc (SNDX) | Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. | SNDX competitors |
| OmniAb Inc. (OABI) | OmniAb Inc. is an innovative biotechnology company dedicated to the development of fully human therapeutic antibodies via its advanced OmniAb platform. | OABI competitors |
| Inventiva Sa (IVA) | Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic... | |
| Climb Bio Inc (CLYM) | Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. | CLYM competitors |
| Neurogene Inc (NGNE) | Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders... | NGNE competitors |
| Adlai Nortye Ltd. American Depositary Shares (ANL) | Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. | |
| Theravance Biopharma Inc (TBPH) | Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe... | |
| Janux Therapeutics Inc (JANX) | Janux Therapeutics, Inc., a biopharmaceutical company, develops therapies based on the patented Tumor Activated T Cell Engager (TRACTr) platform technology... | JANX competitors |
| Regenxbio Inc (RGNX) | REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable... | RGNX competitors |
| DBV Technologies (DBVT) | DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. | DBVT competitors |
| Jade Biosciences, Inc. (JBIO) | Jade Biosciences, Inc. is a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune... | JBIO competitors |
Frequently Asked Questions About ANNX
Who are Annexon's main competitors?
The companies most similar to Annexon include Alto Neuroscience (ANRO), Syndax Pharmaceuticals (SNDX), OmniAb (OABI), Inventiva Sa (IVA) and Climb Bio (CLYM), listed from the closest match.
Who is Annexon's biggest competitor?
Alto Neuroscience (ANRO) is both the largest of the similar companies at $1.18B and the closest match by business profile, size, sector and industry.
How does ANNX stock compare with its competitors?
ANNX's net margin is 0.0% against a peer median of 0.0%.
Which of Annexon's competitors pays a higher dividend?
Annexon pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Annexon bigger than its competitors?
No. Annexon is 6th by market cap among the 13 companies on this page; the largest is Alto Neuroscience (ANRO) at $1.18B.
ANNX pages: Overview, Earnings, Forecast, Financials, Competitors